This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
However, Ioseliani died of a heart attack in March 2003. When the Mkhedrioni failed to secure registration to stand in elections under its own name, it reconstituted itself in November 2002 as a political party called the Union of Patriots in alliance with former Gamsakhurdia supporters. It was again refused registration by the government. Its leader Badri Zarandia was assassinated on January 8, 2003.
== Natural function == Capsaicin is present in large quantities in the placental tissue (which holds the seeds), the internal membranes and, to a lesser extent, the other fleshy parts of the fruits of plants in the genus Capsicum. The seeds themselves do not produce any capsaicin, although the highest concentration of capsaicin can be found in the white pith of the inner wall, where the seeds are attached. The seeds of Capsicum plants are dispersed predominantly by birds. In birds, the TRPV1 channel does not respond to capsaicin or related chemicals, but mammalian TRPV1 is very sensitive to it. This is advantageous to the plant, as chili pepper seeds consumed by birds pass through the digestive tract and can germinate later, whereas mammals have molar teeth that destroy such seeds and prevent them from germinating. Thus, natural selection may have led to increasing capsaicin production because it makes the plant less likely to be eaten by animals that do not help it disperse. There is also evidence that capsaicin may have evolved as an anti-fungal agent. The fungal pathogen Fusarium, which is known to infect wild chilies and thereby reduce seed viability, is deterred by capsaicin, which thus limits this form of predispersal seed mortality. The vanillotoxin-containing venom of a certain tarantula species (Psalmopoeus cambridgei) activates the same pathway of pain as is activated by capsaicin. It is an example of a shared pathway in both plant and animal anti-mammalian defense.
=== Shortenings === Shortenings, because they are widely used, are of particular concern. Baking shortenings, unless reformulated, contain around 30% trans fats compared to their total fats. High-fat dairy products such as butter contain about 4%. Margarines not reformulated to reduce trans fats may contain up to 15% trans fat by weight, but some reformulated ones are less than 1% trans fat. Shortenings for deep-frying in restaurants can be used for longer than most conventional oils before becoming rancid. In the early 21st century, non-hydrogenated vegetable oils that have lifespans exceeding that of the frying shortenings became available.
=== 2 September === Thirteen people were killed in an SAF drone strike on a market in Mellit. The SAF-aligned government said that it would continue to open the Adre border crossing with Chad until the end of the year.
Sources: en.wikipedia.org
=== Pain treatment based on cell micro-encapsulation === In 1998, the Altran Foundation prize was awarded to the Toulouse-Rangueil University laboratory, and to the Kappa Biotech company for their pain-treatment project based on cell micro-encapsulation. The micro-encapsulation process stops the organism from rejecting these cells by protecting them in a sphere, thus preventing the immune system from recognizing them. The process involves creating biocompatible micro-membranes which are implanted using in-vitro fertilization which is live allogeneic or xenogenic cells that are wrapped in a semi-permeable immune-sparing membrane using a bioengineering technique known as cell encapsulation for therapeutic purposes. Until recently, the implantation posed a number of productivity problems, as it was taking 15 minutes for one micro-membrane to be implanted. Altran teams stepped in to help solve this problem. Their studies demonstrated that the automated implantation option, using a laser optical guidance system, was the most promising approach. With the cooperation of Tarbes E.N.I. students, Altran consultants developed a robot to automate the microcapsule filling operation using a dual-needle system. The robot is now commercialized.
To infect host cells SeV must first bind to cell surface receptors using its hemagglutinin-neuraminidase (HN) protein. The receptor-virus attaching process triggers a conformational change in HN, which allosterically promotes the viral fusion (F) protein to promote virus envelope – cell membrane fusion. The receptor attachment is cooperative with respect to receptor density. SeV cell entry receptors are represented mainly by glycoproteins and glycolipids. The table below lists all the molecules that have been shown to function as SeV receptors. Human sialoglycoprotein – cluster of differentiation (CD 235a) is an example of glycoproteins that facilitates SeV cell entry. However, other type of proteins that are not glycoproteins also can assist SeV to penetrate cells. Thus, C-type lectin represented by asialoglycoprotein receptor (ASGP-R), ASGR1) has been shown to be able to function as a SeV cell entry receptor. Among glycosphingolipids two types of glycans are serving as SeV receptors. The first type is represented by fucosylated glycans and the second one by sialylated glycans. The number, positioning, and chemical linkage of sialic acid-containing receptors can be an important determinant of the strength and efficiency of viral attachment, which can play an important role both in host and tissue tropism. The expression of molecules that can facilitate SeV cell entry, frequently accelerates carcinogenesis and metastasis development. The asialoglycoprotein receptor is highly expressed in liver cancers.
=== Pyrrolidines and Pyrrolidinophenones === Pyrrolidines are amphetamines with a pyrrolidine group. Pyrrolidinophenones (also called Pyrovalerones) are cathinones (βk-amphetamines) with a pyrrolidine group.
Church's Texas Chicken menu features a variety of fried chicken options alongside classic sides and desserts. Their menu also includes chicken tenders and boneless wings. Accompanying these main dishes are classic Southern sides such as mashed potatoes with gravy, fried okra, coleslaw, corn on the cob and jalapeño peppers. Desserts include honey butter biscuits and apple pie. Church's Texas Chicken restaurants offer a seasonal seafood menu, featuring shrimp and crispy fish. Since 1952, Church's Texas Chicken restaurants have served beverages supplied by The Coca-Cola Company. In 2008, the companies reaffirmed their commitment with the renewal of their existing contract, continuing to provide customers with Coca-Cola beverages. In 2021, Church's Chicken appointed Performance Food Group Company as its exclusive distributor in the United States to 2026.
Germany has a social market economy with a highly skilled labour force, a low level of corruption, and a high level of innovation. It is the largest economy in Europe by nominal GDP, as well as the world's third-largest by nominal GDP and sixth-largest by PPP-adjusted GDP. Its PPP-adjusted GDP per capita amounted to 115% of the EU average in 2024. The country's service sector contributes approximately 72% of the total GDP, the industrial sector 27%—with Germany having the largest manufacturing output in Europe—and its agricultural sector 1%, as of 2023. The unemployment rate published by Eurostat amounts to 3.2% as of January 2020, which is the fourth-lowest in the EU. Germany is part of the European single market which represents more than 450 million consumers. In 2017, the country accounted for 28% of the eurozone economy according to the International Monetary Fund. Germany introduced the common EU currency, the euro, in 2002. Its monetary policy is set by the European Central Bank, which is based in Frankfurt, the country's largest financial centre. Germany is the world's third-largest exporter and third-largest importer, and it has the second-largest trade surplus after China. Its largest trading partners in 2025 were China, the United States and the Netherlands. Germany's main exports are vehicles, machinery, and chemical goods. The German automotive industry is among the most competitive and innovative in the world. It was the sixth-largest by production and largest by export value in 2023.
Sources: en.wikipedia.org
These are acute medicine, cardiology, Clinical Pharmacology and Therapeutics, endocrinology and diabetes mellitus, gastroenterology, infectious diseases, renal medicine, respiratory medicine and often, rheumatology. The role of general medicine, after a period of decline, was reemphasised by the Royal College of Physicians of London report from the Future Hospital Commission (2013).
== Current usage == Many "omes" beyond the original "genome" have become useful and have been widely adopted by research scientists. "Proteomics" has become well-established as a term for studying proteins at a large scale. "Omes" can provide an easy shorthand to encapsulate a field; for example, an interactomics study is clearly recognisable as relating to large-scale analyses of gene-gene, protein-protein, or protein-ligand interactions. Researchers are rapidly taking up omes and omics, as shown by the explosion of the use of these terms in PubMed since the mid-1990s.
A cDNA for this reductase has been cloned from the orchid Bromheadia finlaysoniana. Researchers in Japan have genetically manipulated roses by using RNA interference to knock out the endogenous enzyme and add a gene for an alternative reductase found in an iris; or add a gene for the blue pigment, delphinidin, to create a blue rose, which is being sold worldwide. Dihydrokaempferol 4-reductase is also an enzyme on the lignin biosynthesis pathway. In Arabidopsis thaliana, the enzyme uses sinapaldehyde or coniferyl aldehyde or coumaraldehyde to produce sinapyl alcohol or coniferyl alcohol or coumaryl alcohol respectively.
The exception is the gasoline engine powered unit, which requires a much higher level of training and topside supervision for safe use. The air-line breathing air compressor compresses clean atmospheric air and stores it in a receiver tank, using an overpressure valve to limit the pressure. The air passes through a filter and the air hose to the diver's demand valve. Small 12 volt diaphragm compressors are used for recreational hookah, with a delivery of around 1.8 bars (26 psi), which severely limits the depth to which air can be supplied. The rubber diaphragm pump usually requires no oil lubricant and delivers oil-free air. Piston compressors for hookah deliver air at higher pressures, up to about 9 bars (130 psi), and are usually driven by a small 4-stroke petrol engine. They are usually oil lubricated, using a breathing air rated mineral or synthetic oil without toxic additives. This type of compressor requires a filter to clean the air before delivery to the diver. Delivery pressure for 12 metres (39 ft) is about 20 to 35 pounds per square inch (1.4 to 2.4 bar) using a hookah regulator. Depths of 40 metres (130 ft) require up to 9 bars (130 psi). The pressure relief valve will blow off excess air delivered at low demand, to protect the system from overpressure loads, while delivering sufficient air for higher exertion. The air line hose should be rated for breathing air, with a bore of 8 to 10 millimetres (0.31 to 0.39 in). It is usually buoyant to minimise snagging on the bottom, particularly if not tended from the surface.
=== Other live performances === Clipse performed at the DuSable Black History Museum in Chicago, Illinois on August 24, 2024, for the Pepsi Dig In Day Block Party—a free event celebrating Black-owned restaurants. Clipse performed "Ace Trumpets" on June 26, 2025, for A Colors Show—a live performance series by German media company ColorsxStudios. Audio of the performance was released as a single on streaming services the same day. They performed an NPR Tiny Desk concert on July 11, concurrently with the album's release. A few days later, on July 15, they performed "The Birds Don't Sing" on The Tonight Show Starring Jimmy Fallon. During 2025 Jubilee, the "World Meeting on Human Fraternity 2025" took place on the St. Peter's Square at the Vatican City on 12 and 13 September, with concert of Andrea Bocelli, Pharrell Williams with the gospel choir Voices of Fire, and John Legend. Clipse performed the song "The Birds Don't Sing" along with John Legend at the second date during the Grace For The World concert on September 13, making history for being the first rappers to ever perform at the Vatican City. The duo performed "So Be It" on Jimmy Kimmel Live! in October 2025.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.